Back to Journals » Journal of Pain Research » Volume 13

Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial

Authors Raeissadat SA, Nouri F, Darvish M, Esmaily H, Ghazihosseini P

Received 28 May 2019

Accepted for publication 24 December 2019

Published 14 January 2020 Volume 2020:13 Pages 109—121

DOI https://doi.org/10.2147/JPR.S217419

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Michael A Überall


Seyed Ahmad Raeissadat, 1, 2 Farshad Nouri, 2 Mahtab Darvish, 1, 2 Hadi Esmaily, 3 Parsa Ghazihosseini 1, 2

1Clinical Research Development Center, Shahid Modarres Hospital, Tehran, Iran; 2Physical Medicine and Rehabilitation Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence: Mahtab Darvish
Physical Medicine and Rehabilitation Research Center, Shahid Modarres Hospital, Saadat Abad St., Yadegare Imam Highway, Tehran 1998734383, Iran
Tel/Fax +982122832343
Email mahtab.darvish@sbmu.ac.ir
Hadi Esmaily
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Niayesh Highway, Valiasr Ave, Tehran 6153-14155, Iran
Tel +98 9121579064
Email Esmaily_hadi@sbmu.ac.ir

Background and Aims: Plantar fasciitis (PF) is the leading cause of heel pain in adults. This study was designed to evaluate the effect of hyaluronic acid (HA) injection in reducing the symptoms of PF, compared with corticosteroid (CS) injection as a conventional treatment.
Methods: In this triple-blind, randomized, clinical trial, 75 patients who had the symptoms of PF for at least 3 months were randomly divided into two groups of 38 and 37 individuals. Then, each patient received either a single injection of high molecular weight (> 2000 kDa) HA (1 mL HA 20 mg + 1 mL lidocaine 2%) or CS (1 mL methylprednisolone 40 mg + 1 mL lidocaine 2%) under the ultrasonography (US) guidance. Visual analog scale (VAS), foot ankle ability index (FAAI), pressure pain threshold (PPT), functional foot index (FFI), and plantar fascia thickness (PFT) were measured using US at baseline, 6 weeks and 24 weeks after the injection. Eventually, at the end of the treatment period, the patients’ satisfaction was measured. Intention to treat analysis was used to assess the results.
Results: After 24 weeks of follow-up, results from 60 subjects were fully obtained; however, results of 73 patients included into intention to treat analysis in the sixth-week follow-up. In both groups, VAS, PFT and FFI decreased, while FAAI and PPT increased significantly (P < 0.001). At the baseline and at the 24th-week, no significant difference between the two groups was observed in any of the variables. However, a comparison between the baseline and the sixth-week results shows a prominent decrease in PPT and PFT in the CS group compared to the HA group (P = 0.004 and P = 0.011). Finally, there were no statistical differences between the two groups in treatment satisfaction (P = 0.618).
Conclusion: Both CS and HA were effective modalities for PF and can improve pain and function with no superiority in 24th-week follow-ups, although CS seems to have a faster trend of improvement in the short term.

Keywords: plantar fasciitis, hyaluronic acid, pain, visual analog scale, patient satisfaction, ankle joint

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]